as screening MRI and WB-US, and for genetic counseling and risk reduction efforts. EDITOR Kerrin M. Green, MA, Assistant Managing Editor, Journal of the National Comprehensive Cancer Network Disclosure: Kerrin M. Green, MA, has disclosed no relevant
Search Results
Renee W. Pinsky and Mark A. Helvie
Robert W. Carlson, D. Craig Allred, Benjamin O. Anderson, Harold J. Burstein, W. Bradford Carter, Stephen B. Edge, John K. Erban, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Lori J. Goldstein, William J. Gradishar, Daniel F. Hayes, Clifford A. Hudis, Britt-Marie Ljung, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Lori J. Pierce, Elizabeth C. Reed, Mary Lou Smith, George Somlo, Neal S. Topham, John H. Ward, Eric P. Winer, and Antonio C. Wolff
noninvasive lesion. Diagnostic evaluation of LCIS is described in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Breast Cancer Screening and Diagnosis, and genetic counseling is recommended if the patient is considered to be at high
Margaret A. Tempero, Mokenge P. Malafa, Mahmoud Al-Hawary, Stephen W. Behrman, Al B. Benson III, Dana B. Cardin, E. Gabriela Chiorean, Vincent Chung, Brian Czito, Marco Del Chiaro, Mary Dillhoff, Timothy R. Donahue, Efrat Dotan, Cristina R. Ferrone, Christos Fountzilas, Jeffrey Hardacre, William G. Hawkins, Kelsey Klute, Andrew H. Ko, John W. Kunstman, Noelle LoConte, Andrew M. Lowy, Cassadie Moravek, Eric K. Nakakura, Amol K. Narang, Jorge Obando, Patricio M. Polanco, Sushanth Reddy, Marsha Reyngold, Courtney Scaife, Jeanne Shen, Charles Vollmer Jr., Robert A. Wolff, Brian M. Wolpin, Beth Lynn, and Giby V. George
cancer for whom a hereditary cancer syndrome is suspect should be considered for genetic counseling. 109 The panel emphasizes the importance of taking a thorough family history when seeing a new patient with pancreatic cancer. In particular, a family
Stephanie A. Terezakis and Nancy Y. Lee
the presence of MTC. Because MTC has high penetrance in all 3 familial forms, first-degree relatives of a family member with the mutation should receive genetic counseling and testing if the patient index demonstrates the RET mutation. 10 , 11 The
William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon H. Giordano, Matthew P. Goetz, Lori J. Goldstein, Steven J. Isakoff, Janice Lyons, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena S. Moran, Ruth M. O'Regan, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Amy Sitapati, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda L. Telli, John H. Ward, Rashmi Kumar, and Dorothy A. Shead
and is not required. Genetic counseling is recommended if the patient is considered to be at high risk for hereditary breast cancer as defined by the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian (available at NCCN
Jill R. Tichy, Elgene Lim, and Carey K. Anders
. Cowden disease, caused by mutations in the PTEN gene, is exceedingly rare and is also associated with other tumors, particularly of the skin, thyroid, and endometrium. 39 Genetic counseling plays a paramount role in decision-making for young women
NCCN Guidelines Insights: Prostate Cancer, Version 1.2021
Featured Updates to the NCCN Guidelines
Edward Schaeffer, Sandy Srinivas, Emmanuel S. Antonarakis, Andrew J. Armstrong, Justin E. Bekelman, Heather Cheng, Anthony Victor D’Amico, Brian J. Davis, Neil Desai, Tanya Dorff, James A. Eastham, Thomas A. Farrington, Xin Gao, Eric Mark Horwitz, Joseph E. Ippolito, Michael R. Kuettel, Joshua M. Lang, Rana McKay, Jesse McKenney, George Netto, David F. Penson, Julio M. Pow-Sang, Robert Reiter, Sylvia Richey, Mack Roach, III, Stan Rosenfeld, Ahmad Shabsigh, Daniel E. Spratt, Benjamin A. Teply, Jonathan Tward, Dorothy A. Shead, and Deborah A. Freedman-Cass
tumor MSI-H or dMMR is identified, the panel recommends referral to genetic counseling for consideration of germline testing for Lynch syndrome. New Systemic Therapy Options for CRPC PARP Inhibitors for Patients With DNA Repair Gene Mutations Results of
Peter R. Carroll, J. Kellogg Parsons, Gerald Andriole, Robert R. Bahnson, Erik P. Castle, William J. Catalona, Douglas M. Dahl, John W. Davis, Jonathan I. Epstein, Ruth B. Etzioni, Thomas Farrington, George P. Hemstreet III, Mark H. Kawachi, Simon Kim, Paul H. Lange, Kevin R. Loughlin, William Lowrance, Paul Maroni, James Mohler, Todd M. Morgan, Kelvin A. Moses, Robert B. Nadler, Michael Poch, Chuck Scales, Terrence M. Shaneyfelt, Marc C. Smaldone, Geoffrey Sonn, Preston Sprenkle, Andrew J. Vickers, Robert Wake, Dorothy A. Shead, and Deborah A. Freedman-Cass
-Risk Assessment: Breast and Ovarian. These latter guidelines include personalized risk assessment, genetic counseling, and possible genetic testing for individuals with a personal history of prostate cancer and 1 or more close blood relatives with breast cancer
Yvonne Bombard, Peter B. Bach, and Kenneth Offit
Examples: BRCA Testing for Breast and Ovarian Cancer Susceptibility: The report by the USP-STF considered the impact of genetic counseling on psychosocial response to BRCA testing (eg, anxiety, depression, cancer risk perception, uptake) and found
18% were referred to genetic counseling. Results are presented in Table 1 . Conclusions: The Athena model effectively identifies women previously unaware of their elevated breast cancer risk status. The findings support the value and efficiency of
